Lugano, Switzerland – The Molecular Analysis for Precision Oncology Congress 2024 (MAP) is the appointment where globally recognised experts will present and discuss research in precision medicine, technologies for cancer profiling, mechanisms driving tumour expansion, metastatic dissemination, clonal evolution, and biomarker-driven development of targeted therapeutics. The congress will be held onsite in London, UK, from 16-18 October, with no virtual option available.
Programme highlights
- Development of a computational approach to identify and interpret variants of unknown significance (VUS) in cancer patients.
- Related content: Abstract 1O
- Findings on CTCs and ctDNA detection as prognostic and predictive biomarkers in colorectal cancer patients receiving adjuvant treatment.
- Related content: Abstract 9P
- New insights into the mechanism of resistance to endocrine therapy in metastatic breast cancer.
- Related content: Abstract 146P
- Novel data on the correlation between the recommendations on cost effectiveness and the clinical benefits of cancer therapeutics developed by NICE (the National Institute for Health and Care Excellence) and the ESMO assessment tools ESMO-MCBS (ESMO-Magnitude of Clinical Benefit Scale) and ESCAT (ESMO Scale for Clinical Actionability of molecular Targets) to align the decision-making process on cancer drugs.
- Related content: Abstract 103P
Keynote lectures
- “Clinical translation of new spatial transcriptomics technologies” by Joakim Lundeberg, 16 October 2024, 13:00 – 13:30 CEST
- “Clonal genomics and solid tumours / haematological malignancies” by Elli Papaemmanuil 16 October 2024, 13:00-13:30 CEST
The results of 174 studies from various parts of the world will be presented and published online as a supplement to ESMO Open. The abstract titles can be viewed through the online programme.
Press accreditation
The MAP organisers welcome press representatives working for recognised press outlets interested in obtaining information and reporting on cancer issues, upon presentation of a letter of assignment and a valid press card. Press representatives are required to observe and abide by the ESMO Policy on Press Activities and the embargo schedule for MAP 2024. To apply for press accreditation, please fill out the form available here. Please be kindly informed that onsite press accreditations will not be available.
Third Parties Media registration
Third Parties Media representatives and Filming Crews not eligible as press, must abide by the ESMO Policy on Media Activities Organised by Third Parties and can request a Third Parties Media badge through registration@esmo.org (Cc media@esmo.org).
Further information
MAP Press Office
press@esmo.org
MAP is a joint initiative of Cancer Research UK (CRUK), Unicancer and the European Society for Medical Oncology (ESMO).
Notes to Editors
Please make sure to use the official name of the meeting in your reports: MAP 2024 and the official congress hashtag #MAP2024. Follow it to stay up to date and use it to take part in the conversation on X(Twitter), LinkedIn, Facebook, Instagram, YouTube.